Skip to main content
. Author manuscript; available in PMC: 2009 Sep 1.
Published in final edited form as: J Pineal Res. 2008 Mar 26;45(2):117–124. doi: 10.1111/j.1600-079X.2008.00582.x

Fig. 4. Alterations in expression of Bax and Bcl-2 at mRNA and protein levels.

Fig. 4

(A) Representative agarose gels to show mRNA levels of bax, bcl-2, and GAPDH genes (reverse transcription-polymerase chain reaction). (B) Representative Western blots to show protein levels of Bax, Bcl-2, and GAPDH (Western blotting). (C) Densitometric analysis showing the Bax:Bcl-2 ratio in six treatment groups. Treatment groups (panels A–C): control (CTL); 150 nm melatonin (24 hr); 500 µm l-glutamic acid (LGA) (24 hr); 500 µm LGA (15 min) + melatonin post-treatment (24 hr); 100 µm H2O2 (24 hr); and 100 µm H2O2 (15 min) + melatonin post-treatment (24 hr).